Articles for category: Most Popular

QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway

uniQure N.V. QURE remains a catalyst-driven gene therapy stock, with AMT-130 shaping most of the investment debate. The program targets Huntington’s disease, an area where disease-modifying options remain absent. Recent FDA feedback, a targeted biologics license application submission in the third quarter of 2026 and a cash runway into the second half of 2029 now ...

Why Apple Stock Climbed to a New All-Time High Today

Key Points Innovative new tech could bring the power of advanced AI models to the iPhone. Partnerships with Chinese cloud leaders will help Apple bring AI services to its largest international market. 10 stocks we like better than Apple › Shares of Apple (NASDAQ: AAPL) jumped to a record high on Wednesday, following some positive ...

The Nile Flooded Every Year — So Does This Stock

Stocks have tended to rise and fall in the past with remarkable accuracy during specific windows of time… Listen to the audio version of this article (generated by AI). Editor’s Note: Looking back can often help us see what’s likely to happen next. That approach has enabled Keith Kaplan and his team at TradeSmith to ...

Taiwan Semiconductor Manufacturing Just Showed the Artificial Intelligence (AI) Build-Out Is Alive and Well With This Jaw-Dropping Announcement

Key Points Taiwan Semiconductor Manufacturing (NYSE: TSM) may be one of the most important companies to the health of the AI infrastructure build-out. Its foundries churn out the logic chips designed by nearly every one of the major players in the space, and it just made an announcement that supports the idea that we’re still ...

What Do SpaceX, AMD, and Palantir Have in Common?

Key Points Space Exploration Technologies (NASDAQ: SPCX), AMD (NASDAQ: AMD), and Palantir Technologies (NASDAQ: PLTR) may seem like an odd grouping of companies. But I have a good reason to consider them together: They’re all incredibly overvalued. While that may sound like a shocking statement, after digging into each stock, that’s the reality, and investors ...

uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix

uniQure N.V. QURE now represents more than a single-program gene therapy story. Its profile is being reshaped by faster regulatory pathways, a narrower operating model and clinical work in rare neurological diseases. Those trends matter because investors are watching whether uniQure can build the next phase of growth beyond HEMGENIX-related economics and obligations. uniQure Is ...